Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study.

Graziano SL, Tatum A, Herndon JE 2nd, Box J, Memoli V, Green MR, Kern JA.

Lung Cancer. 2001 Aug-Sep;33(2-3):115-23.

PMID:
11551406
2.

Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study.

Graziano SL, Kern JA, Herndon JE, Tatum A, Brisson ML, Memoli V, Sugarbaker D, Skarin AT, Kreisman H, Green MR.

Lung Cancer. 1998 Sep;21(3):203-11.

PMID:
9857998
3.

The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer.

Gajra A, Tatum AH, Newman N, Gamble GP, Lichtenstein S, Rooney MT, Graziano SL.

Lung Cancer. 2002 May;36(2):159-65.

PMID:
11955650
4.

Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors.

Ludovini V, Pistola L, Gregorc V, Floriani I, Rulli E, Di Carlo L, Semeraro A, Daddi G, Darwish S, Stocchi L, Tofanetti FR, Bellezza G, Sidoni A, Tognellini R, Crinò L, Tonato M.

Tumori. 2008 May-Jun;94(3):398-405.

5.

The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer.

Graziano SL, Tatum AH, Newman NB, Oler A, Kohman LJ, Veit LJ, Gamble GP, Coleman MJ, Barmada S, O'Lear S.

Cancer Res. 1994 Jun 1;54(11):2908-13.

6.

Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection.

Brooks KR, To K, Joshi MB, Conlon DH, Herndon JE 2nd, D'Amico TA, Harpole DH Jr.

Ann Thorac Surg. 2003 Jul;76(1):187-93; discussion 193.

PMID:
12842538
7.

Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer.

Carles J, Rosell R, Ariza A, Pellicer I, Sanchez JJ, Fernandez-Vasalo G, Abad A, Barnadas A.

Lung Cancer. 1993 Dec;10(3-4):209-19.

PMID:
7521264
8.

Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.

Moldvay J, Scheid P, Wild P, Nabil K, Siat J, Borrelly J, Marie B, Farré G, Labib T, Pottier G, Sesboüé R, Bronner C, Vignaud JM, Martinet Y, Martinet N.

Clin Cancer Res. 2000 Mar;6(3):1125-34.

9.

p53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer.

Fijołek J, Wiatr E, Rowińska-Zakrzewska E, Giedronowicz D, Langfort R, Chabowski M, Orłowski T, Roszkowski K.

Int J Biol Markers. 2006 Apr-Jun;21(2):81-7.

PMID:
16847810
10.

Biological markers in non-small cell lung cancer. Retrospective study of 10 year follow-up after surgery.

Carbognani P, Tincani G, Crafa P, Sansebastiano G, Pazzini L, Zoni R, Bobbio A, Rusca M.

J Cardiovasc Surg (Torino). 2002 Aug;43(4):545-8.

PMID:
12124571
11.

[The value of neuroendocrine markers for response to therapy and survival in patients with advanced non-small cell lung cancer].

Petrović M, Ilić N, Baskić D.

Srp Arh Celok Lek. 2010 Jan-Feb;138(1-2):37-42. Serbian.

12.

Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing.

Shaw GL, Gazdar AF, Phelps R, Linnoila RI, Ihde DC, Johnson BE, Oie HK, Pass HI, Steinberg SM, Ghosh BC, et al.

Cancer Res. 1993 Nov 1;53(21):5181-7.

13.

[Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].

Cheng C, Wu YL, Gu LJ, Chen G, Weng YM, Feng WN, Zhong WZ.

Ai Zheng. 2005 Jul;24(7):846-9. Chinese.

PMID:
16004813
14.

Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.

Oyama T, Osaki T, Nose N, Ichiki Y, Inoue M, Imoto H, Yoshimatsu T, Kodate M, Uramoto H, Mizoue T, Yano K, Yasumoto K.

Anticancer Res. 2000 Jan-Feb;20(1B):505-10.

PMID:
10769714
15.

Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer.

Bozcuk H, Gumus A, Ozbilim G, Sarper A, Kucukosmanoglu I, Ozbudak IH, Artac M, Ozdogan M, Samur M, Kaya A, Savas B.

Med Sci Monit. 2005 Jun;11(6):HY11-20. Epub 2005 May 25.

PMID:
15917726
16.

Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer.

Han H, Landreneau RJ, Santucci TS, Tung MY, Macherey RS, Shackney SE, Sturgis CD, Raab SS, Silverman JF.

Hum Pathol. 2002 Jan;33(1):105-10.

PMID:
11823980
17.

Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.

Ludovini V, Gregorc V, Pistola L, Mihaylova Z, Floriani I, Darwish S, Stracci F, Tofanetti FR, Ferraldeschi M, Di Carlo L, Ragusa M, Daddi G, Tonato M.

Lung Cancer. 2004 Oct;46(1):77-85.

PMID:
15364135
18.

[Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].

Huang PY, Liang XM, Lin SX, Luo RZ, Hou JH, Zhang L.

Ai Zheng. 2004 Jul;23(7):845-50. Chinese.

PMID:
15248926
19.

Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.

Hirai K, Koizumi K, Haraguchi S, Hirata T, Mikami I, Fukushima M, Yamagishi S, Kawashima T, Okada D, Shimizu K, Kawamoto M.

Ann Thorac Surg. 2005 Jan;79(1):248-53.

PMID:
15620951
20.
Items per page

Supplemental Content

Write to the Help Desk